Sent on behalf of Welsh Government.
A strong market for biosimilar medicines drives commercial competition and offers a greater choice of affordable biological treatments.
Across the NHS, demand for expensive disease-modifying medicines is increasing. Early adoption and widespread use of biosimilar medicines free up resources so that many more patients benefit from reinvestment in services and improved access to new and innovative therapies.
We would be grateful to receive your comments on this strategy, which sets out the steps the NHS and its partners in Wales will take to support the conditions needed to create a strong, competitive biosimilar medicines market in the UK benefiting the NHS, patients and the economy of Wales.
Please share this email with any colleagues with whom you feel it is appropriate, and who may wish to comment on the draft document.
If you would like to make any comments, please complete the associated pro-forma and send it to awttc@wales.nhs.uk by Wednesday 7 September 2022.
The document and associated pro-forma can be accessed using the following links:
